CD1530 

CD1530 is an orally active, selective RARγ agonist and antibacterial agent. CD1530 reduces Smad1/5/8 phosphorylation and overall Smad levels. CD1530 reduces β-catenin, MMP9 protein, and ROS levels. CD1530 exhibits activities such as inhibiting heterotopic ossification, promoting Achilles tendon healing, and inhibiting muscle fatty infiltration. CD1530 can be used in the research of orthopedic diseases (such as heterotopic ossification, Achilles tendon injury), muscle diseases (such as muscle fatty infiltration-related diseases)^{[1][2][3][4][5][6]}.

CD1530 (1 μM; 24 h) enhances the expression of UCP1 in mature mouse adipocytes^[2].
CD1530 (10-1000 nM; 48 h-3 weeks) significantly enhances the migratory capacity of injured Achilles tendon-derived tendon fibroblasts (iATF) and inhibits the chondrogenic differentiation of iATF^[4].
CD1530 (10 μg/mL; 2 h) reduces the number of methicillin-resistant Staphylococcus aureus (MRSA) below the limit of detection, demonstrating potent in vitro bactericidal activity^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

CD1530 (4 mg/kg; p.o.; once every other day) inhibits FOP-like heterotopic ossification in transgenic mice carrying a Cre-inducible constitutively active ALK2^Q207D mutation^[1].
CD1530 (2.5 mg/100 mL; p.o., in drinking water; frequency not mentioned; 15 weeks) combined with 4-nitroquinoline 1-oxide reduces the number and severity of tongue tumor lesions in mice with oral cancer^[3].
CD1530 (10 μg; local injection; 3 times per week; 3 weeks) accelerates tendon healing in mice with Achilles tendon rupture, inhibits cartilage formation, reduces fibrous tissue-like scar formation, and promotes better collagen fiber alignment^[4].
CD1530 (4 mg/kg, p.o.; or 1 mM, intramuscular injection; once a day; administration for 4 weeks) can inhibit muscle fat infiltration, reduce the number of intramuscular adipocytes, and reduce the expression of adipogenic marker genes in mice with rotator cuff tear^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

398.49

C₂₇H₂₆O₃

107430-66-0

Solid

Light brown to brown

O=C(O)C1=CC=C(C2=CC=C3C=C(O)C(C4(C5)CC6CC5CC(C6)C4)=CC3=C2)C=C1

Room temperature in continental US; may vary elsewhere.

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

• [1]. Shimono K, et al. Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor-γ agonists. Nat Med. 2011 Apr;17(4):454-60.  [Content Brief]

  [2]. Murholm M, et al. Retinoic acid has different effects on UCP1 expression in mouse and human adipocytes. BMC Cell Biol. 2013 Sep 23;14:41.  [Content Brief]

  [3]. Tang XH, et al. Combination of bexarotene and the retinoid CD1530 reduces murine oral-cavity carcinogenesis induced by the carcinogen 4-nitroquinoline 1-oxide. Proc Natl Acad Sci U S A. 2014 Jun 17;111(24):8907-12.  [Content Brief]

  [4]. Yimiti D, et al. CD1530, selective RARγ agonist, facilitates Achilles tendon healing by modulating the healing environment including less chondrification in a mouse model. J Orthop Res. 2025 Feb;43(2):273-284.  [Content Brief]

  [5]. Kim W, et al. A new class of synthetic retinoid antibiotics effective against bacterial persisters. Nature. 2018 Apr 5;556(7699):103-107.  [Content Brief]

  [6]. Shirasawa H, et al. Retinoic Acid Receptor Agonists Suppress Muscle Fatty Infiltration in Mice. Am J Sports Med. 2021 Feb;49(2):332-339.  [Content Brief]